Alliance Pharma plc (AIM: APH), the international healthcare group, will hold its Annual General Meeting (“AGM”) at 10:00am this morning. At the meeting, the Group’s Chair, David Cook, will make the following statement:
“Firstly, on behalf of the Alliance Board, I would like to take this opportunity to thank Alliance’s employees around the world for their continued commitment and support.
“The overall business is in good health and consumer demand for our brands remains strong. The integration of ScarAway and the rights to Kelo-cote in the US (acquired in March 2022) is progressing well.
“In line with the comments made at the FY 2021 results in March 2022, we continue to expect FY 2022 performance to be weighted to H2 due to our anticipated sales trajectory for Amberen and Nizoral, together with temporary disruption to our supply chain through COVID-related lockdowns in China, which is now beginning to ease.”
David Cook, Groups Chairman of Alliance will comment:“We remain confident in our ability to deliver full year financial performance in line with market expectations. Further commentary on our first half trading performance will be provided in our trading update in July 2022.”
For further information:
Alliance Pharma plc
Cora McCallum, Head of Investor Relations & Corporate Communications
+ 44 (0)1249 466966
+ 44 (0)1249 705168
ir@allianceph.com
Buchanan
Mark Court / Sophie Wills / Hannah Ratcliff
+ 44 (0)20 7466 5000
alliancepharma@buchanan.uk.com
Numis Securities Limited
Nominated Adviser: Freddie Barnfield / Duncan Monteith
Corporate Broking: James Black
+ 44 (0)20 7260 1000
Investec Bank plc
Corporate Finance: Daniel Adams
Corporate Broking: Patrick Robb
+ 44 (0)20 7597 5970
About Alliance
Alliance Pharma plc (AIM: APH) is an international healthcare group. Our purpose is to improve the lives of consumers and patients through making available a range of clinically valuable healthcare products.
Our core focus is on the marketing of Consumer Healthcare brands, complemented by a smaller Prescription Medicines business. In total, we hold marketing rights to around 80 brands, with revenues generated from a mix of direct, distributor and e-commerce sales.
Headquartered in the UK, the Group employs around 250 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics operations, we remain asset-light and focused on maximising the value of our brands.
For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com